Author response for "Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( <scp>SWITCH‐SEMA</scp> 1 study)"